New drugs and new targets

Drug News and Perspectives

Volumn 17, Issue 9, 2004, Pages 615-632

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (2,5 DIMETHYLPHENYL) 3 (TRIFLUOROMETHYL) 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; APOCYNIN; ASCORBIC ACID; CELECOXIB; CLOZAPINE; DICLOFENAC; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; IDAZOXAN; INDOMETACIN; KETOPROFEN; METHYLPREDNISOLONE; MIRTAZAPINE; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OSU 03012; OSU 03013; PARACETAMOL; PIRENZEPINE; PRESYNAPTIC RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RACLOPRIDE; REBOXETINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROFECOXIB; SUMATRIPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTICOAGULATION; ASTHMA; AUSTRALIA; BLOOD VESSEL INJURY; CANCER THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; LIPODYSTROPHY; MIGRAINE; NONHUMAN; OBESITY; OSTEOPOROSIS; PHARMACOGENOMICS; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA;

ANTINEOPLASTIC AGENTS; AUDIOVISUAL AIDS; AUSTRALIA; CEREBROVASCULAR ACCIDENT; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPERTENSION; LONG QT SYNDROME; MYOCARDIAL ISCHEMIA; NADPH OXIDASE; OBESITY; OSTEOPOROSIS; PHARMACISTS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PRESYNAPTIC; SCHIZOPHRENIA; SOCIETIES, SCIENTIFIC;

EID: 12344312300     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (106)

1. Sarkar, S., Fekete, C., Legradi, G. and Lechan, R.M. Glucagon-like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotrophin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 2003, 985: 163-8.
2. Hilfiker, S. Neuronal calcium sensor-1: A multifunctional regulator of secretion. Biochem Soc Trans 2003, 31: 828-32.
3. Hertel, P., Fagerquist, M.V. and Svensson, T.H. Enhanced cortical output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999, 286: 105-7.
4. Linner, L., Wiker, C., Wadenberg, M.L., Schalling, M. and Svensson, T.H. Noradrenaline reuptake inhibition enhances the anti-psychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002, 27: 691-8.
5. Litman, R.E., Su, T.P., Potter, W.Z., Hong, W.W. and Pickar, D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptics, clozapine. Br J Psychiatry 1996, 168: 571-9.
6. Stanhope, K.J., Mirza, N.M., Birkerdike, M.J. et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 2001, 299: 782-92.
7. Sur, C., Mallorga, P.J., Wittmann, M. et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003, 100: 13674-9.
8. Fitzgerald, G.A. and Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345: 433-42.
9. Garcia Rodriquez, L.A., Varas-Lorenzo, C., Maguire, A. and Gonzales-Perez, A. Nonsteroidal anti-inflammatory drugs and risk of myocardial infarction in the general population. Circulation 2004, 109: 3000-6.
10. Kojima, F., Naraba, H., Sasaki, Y, Okamoto, R., Koshino, T. and Kawai, S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol 2002, 29: 1836-42.
11. Kojima, E, Naraba, H., Sasaki, Y., Beppu, M., Aoki, H., Kawai, S. Prostaglandin E2 is an enhancer of interleukin-1 beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 2003, 48: 2819-28.
12. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S. and Kawai, S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 2002, 302: 18-25.
13. Kusunoki, N., Yamazaki, R. and Kawai, S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002, 46: 3159-67.
14. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S. and Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit apoptosis of colon adenocarcinoma cells. FEBS Lett 2002, 531: 278-84.
15. Steinbach, G., Lynch, P.M., Phillips, R.K. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342: 1946-52.
16. Subbaramaiah, K. and Dannenberg, A.J. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24: 96-102.
17. Niederberger, E., Tegeder, I., Vetter, G. et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 2001, 15: 1622-4.
18. Kulp, S.K., Yang, Y.T., Hung, C.C. et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004, 64: 1444-51.
19. Zhu, J., Huang, J.W., Tseng, P.M. et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitor. Cancer Res 2004, 64: 309-18.
20. Iniguez, M.A., Rodriguez, A., Volpert, O.V., Fresno, M. and Redondo, J.M. Cyclooxygenase-2: A therapeutic target in angiogenesis. Trends Mol Med 2003, 9: 73-8.
21. Yusuf, S., Dagenais, C., Pogue, J., Bosch, J. and Sleight, P. Vitamin E supplementation and cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 154-60.
22. Hodis, H.N., Mack, W.J., LaBree, L. et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002, 106: 1453-9.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 260: 23-33.
24. Paravicini, T.M., Gulluyan, L.M., Dusting, G.J. and Drummond, G.R. Increases NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ Res 2002, 91: 54-61.
25. Burgess, J.K., Johnson, P.R., Ge, Q. et al. Expression of connective tissue growth factor in asthmatic airway smooth muscle cells. Am J Respir Crit Care Med 2003, 167: 71-7.
26. Chambers, L.S., Black, J.L., Ge, Q. et al. PAR-2 activation, PGE2, and COX-2 in human asthmatic and nonasthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003, L619-27.
27. Rosenbaum, M., Leibel, R.L., Hirsch, J. Obesity. N Engl J Med 1997, 337: 396-407.
28. Klein, S., Fontana, L., Young, V.L. et al. Absence of an effect of liposuction on Insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350: 2549-57.
29. Markovic, T.P., Jenkins, A.B., Campbell, L.V., Furier, S.M., Kraegen, E.W. and Chisholm, D.J. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998, 687-94.
30. Markovic, T.P., Campell, L.V., Balasubramanian, S. et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care 1998, 21: 695-700.
31. Bi, S., Scott, K.A., Kopin, A.S. and Moran, T.H. Differential roles for cholecystokinin A receptors in energy balance in rats and mice. Endocrinology 2004, 145: 3873-80.
32. Naslund, E., King, N., Mansten, S. et al. Prandial subcutaneous injections of glucagon-like peptide-1 causes weight loss in obese human subjects. Br J Nutr 2004, 91: 439-46.
33. Batterham, R.L., Cowley, M.A., Small, C.J. et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418: 650-4.
34. Batterham, R.L., Cohen, M.A., Ellis, S.M. et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349: 941-8.
35. Pittner, R.A., Moore, C.X., Bhavsar, S.P. et al. Effects of PYY3-36 in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004, 28: 963-71.
36. Challis, B.C., Pinnock, S.B., Coll, A.P. et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Comm 2003, 311: 915-9.
37. Tschop, M., Castaneda, T.R., Joost, H.G. et al. Physiology: Does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004, 430: 1.
38. Cummings, D.E., Weigle, D.S., Frayo, R.S. et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346: 1623-30.
39. Neary, N.M., Small, C.J., Wren, A.M. et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89: 2832-6.
40. Kumada, M., Kihara, S., Sumitsuji, S. et al. Association of hypoadiponectinemia with coronary artery disease in men. Arteriorscler Throm Vasc Biol 2003, 23: 85-9.
41. Lindsay, R.S., Funahashi, T., Hanson, R.L. et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360: 57-8.
42. Iwashima, Y., Katsuya, T., Ishikawa, K. et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43: 1318-23.
43. Ouchi, N., Kihara, S., Arita, Y. et al. Adiponectin, and adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102: 1296-301.
44. Maeda, N., Takahashi, M., Funahashi, T. et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-9.
45. Yang, W.S., Jeng, C.Y., Wu, T.J. et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25: 376-80.
46. Friis-Moller, N., Sabin, C.A., Weber, R. et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349: 1993-2003.
47. Smith, D.E., Carr, A., Law, M. et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: The PIILR extension study. AIDS 2002, 16: 2489-91.
48. Carr, A., Workman, C., Smith, D.E. et al. Abacavir substitution for nucleoside analogs in patients with lipoatrophy: A randomized trial. JAMA 2002, 288: 207-15.
49. Engelson, E.S. HIV lipodystrophy diagnosis and management. Body composition and metabolic alterations: Diagnosis and management. AIDS Read 2003, 13(4 Suppl): S10-4.
50. Carr, A., Workman, C., Carey D. et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004, 363: 429-38.
51. Moyle, G.J., Lysakova, L., Brown, S. et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004, 5: 82-7.
52. Black, S.C. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004, 5: 389-94.
53. Lambert, P.D., Anderson, K.D., Sleeman, M.W. et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001, 98: 4652-7.
54. Sleeman, M.W., Garcia, K., Liu, R. et al. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Prod Natl Acad Sci USA 2003, 100: 14297-302.
55. Ljung, B., Bamberg, K., Dahllof, B. et al. AZ 242,a novel PPARalpha/gamma with beneficial effects on insulin resistance and carbohydrate metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002, 43: 1855-63.
56. Etgen, G.J., Oldham, B.A., Johnson, W.T. et al. A tailored therapy for the metabolic syndrome: The dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002, 51: 1083-7.
57. Yajima, K., Hirose, H., Fujita, H. et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 2003, 284: E966-71.
58. Skrumsager, B.K., Nielsen, K.K., Muller, M., Pabst, G., Drake, P.G. and Edsberg, B. Ragaglitazar: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol 2003, 43: 1244-56.
59. Guo, Q., Sahoo, S.P., Wang, P.R. et al. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrated favorable effects on lipid homeostasis. Endocrinology 2004, 145: 1640-8.
60. Yamada, M., Basile, A.S., Fedrova, I. et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 2003, 74: 345-53.
61. Tzavara, E.T., Bymaster, F.P., Felder, C.C. et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003, 8: 673-9.
62. Neubig, R.R. and Siderovski, D.P. Regulators of G-protein signalling as new central nervous system targets. Nat Rev Drug Discov 2002, 1: 187-97.
63. Jin, Y., Zhong, H., Omnaas, J.R., Neubig, R.R. and Mosberg, H.I. Structure-based design, synthesis and pharmacologic evaluation of peptide RGS4 inhibitors. J Peptide Res 2004, 63: 141-6.
64. Chesnut, C.H., III, Silverman, S., Andriano, K. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109: 267-76.
65. Cummings, S.R. and Chapurlat, R.D. What PROOF proves about calcitonin and clinical trials. Am J Med 2000, 109: 330-1.
66. Stafford, R.S., Drieling, R.L. and Hersch, A.L. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004, 164: 1525-30.
67. Reid, I.R., Brown, J.P., Burckhardt, P. et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346: 653-61.
68. Black, D.M., Greenspan, S.L., Ensrud, K.E. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349: 1207-15.
69. Meunier, P.J., Roux, C., Seeman, E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350: 459-68.
70. Bekker, P.J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, PT. and Dunstan, C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16: 348-60.
71. Body, J.J., Griepp, P., Coleman, R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma-related bone metastases. Cancer 2003, 97(3 Suppl): 886-92.
72. Bekker, P.J., Holloway, D.L., Rasmussen, A.D. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19: 1059-66.
73. Hutchinson, J.H., Halczenko, W., Brashear, K.M. et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem 2003, 46: 4790-8.
74. Schaller, S., Henriksen, K., Sveigaard, C. et al. The chloride channel inhibitor NS-3736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19: 1144-53.
75. Cornish, J., Gallon, K.E., Naot, D. et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 2004, 145: 4366-74.
76. Grey, A., Banovic, T., Zhu, Q. et al. The low density lipoprotein-receptor-related protein 1 (LRP1) a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 2004, 18: 2268-78.
77. Wang, L., Zhang, Z., Wang, Y., Zhang, R. and Chopp, M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35: 1732-7.
78. Matsumoto, S., Isshiki, A., Watanabe, Y. and Wieloch, T. Restricted clinical efficacy of cyclosporine A on rat transient middle cerebral artery occlusion. Life Sci 2002, 72: 591-600.
79. Mattiasson, G., Shamloo, M., Gido, G. et al. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 2003, 9: 1062-8.
80. Zhang, W.R., Sato, K., Iwai, M., Nagano, I., Manabe, Y. and Abe, K. Therapeutic time window of adenovirus-mediated GDNF gene transfer after transient middle cerebral artery occlusion in rat. Brain Res 2002, 947: 140-5.
81. Abe, K., Yuki, S. and Kogure, K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988, 19: 480-5.
82. Zhang, W., Sato, K., Hayashi, T. et al. Extension of ischemic therapeutic time window by a free radical scavenger, edaravone, reperfused with tPA in rat brain. Neurol Res 2004, 26: 342-8.
83. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003, 15: 222-9.
84. Toyoda, K., Fujii, K., Kamouchi, M. et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004, 221: 11-7.
85. Syderff, S.G., Borelli, A.R., Green, A.R. and Cross, A.J. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies of dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002, 135: 103-12.
86. Lapchak, P.A., Araujo, D.M., Song, D., Wei, J., Purdy, R. and Zivin, J.A. Effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: Combination studies with tissue plasminogen activator. Stroke 2002, 33: 1665-70.
87. Marshall, J.W., Cummings, R.M., Bowes, L.J., Ridley, R.M. and Green, A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003, 34: 2228-33.
88. Lees, K.R., Barer, D., Ford, G.A. et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003, 34: 482-7.
89. Zhang, L., Zhang, Z.G., Zhang, R. et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation 2003, 107: 2837-43.
90. Chen, J., Zhang, Z.G., Li, Y. et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003, 53: 743-51.
91. Eichelbaum, M., Fromm, M.F. and Schwab, M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004, 26: 180-5.
92. Sordella, R., Bell, D.W., Haber, D.A. and Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004, 20: 1163-7.
93. Morant, S.V., McMahon, A.D., Cleland, J.G., Davey, P.O. and MacDonald, T.M. Cardiovascular prophylaxis with aspirin: Cost of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004, 57: 188-98.
94. Wei, L., Wang, J., Thompson, P., Struthers, A.D. and MacDonald, T.M. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 2002, 88: 229-33.
95. Wald, N.J. and Law, M.R. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003, 326: 1419.
96. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. and Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305: 399-401.
97. Paramore, A., Frantz, S. Bortezomib. Nat Rev Drug Discov 2003, 2: 611-2.
98. Richardson, P.G., Barlogie, B., Berenson, J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348: 2609-17.
99. Chauhan, D., Li, G., Podar, K. et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004, 3158-66.
100. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-42.
101. Yang, J.C., Haworth, L., Sherry, R.M. et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427-34.
102. Miller, K.D. The role of ErbB inhibitors in trastuzumab resistance. Oncologist 2004, 9(Suppl 3): 16-9.
103. Clayton, A.J., Danson, S., Jolly, S. et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91: 639-43.
104. Kris, M.G., Natale, R.B., Herbst, R.S. et al. Efficacy of gefitinib, as inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003, 290: 2149-58.
105. Soulieres, D., Senzer, N.N., Yokes, E.E., Hidalgo, M., Agarwala, S.S. and Siu, L.L. Multicenter phase II study of erlotinib, and oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer or the head and neck. J Clin Oncol 2004, 22: 77-85.
106. Burris, H.A., III. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGRF/Erb-2 inhibitor lapatinib. Oncologist 2004, 9(Suppl 3): 10-3.